- Home
- GNS vs CPHI Comparison
GNS vs CPHI Comparison
Compare GNS & CPHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GNS | CPHI |
|---|---|---|
| Founded | 2002 | N/A |
| Country | Singapore | China |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.1M | 38.1M |
| IPO Year | 2021 | 2008 |
Fundamental Metrics
Financial Performance| Metric | GNS | CPHI |
|---|---|---|
| Price | $0.15 | $0.72 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 3.0M | 129.1K |
| Earning Date | 03-09-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,144,268.00 |
| Revenue This Year | $156.26 | N/A |
| Revenue Next Year | $35.38 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.15 | $0.38 |
| 52 Week High | $1.06 | $19.19 |
Technical Indicators
Market Signals| Indicator | GNS | CPHI |
|---|---|---|
| Relative Strength Index (RSI) | 39.98 | 41.80 |
| Support Level | $0.15 | $0.70 |
| Resistance Level | $0.23 | $0.89 |
| Average True Range (ATR) | 0.01 | 0.04 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 9.36 | 7.57 |
Price Performance
Historical ComparisonAbout GNS Genius Group Limited
Genius Group Ltd is an Edtech and education company that provides entrepreneur education system business development tools and management consultancy services to entrepreneurs and entrepreneur resorts. Its revenue is derived from five reportable segments: Central, Academy, School, Resorts, and Discontinued operations. Geographically, it operates in Europe/Middle East/Africa, Asia/Pacific, and North America/South America.
About CPHI China Pharma Holdings Inc.
China Pharma Holding Inc is a drug manufacturing company. It is mainly engaged in the development, manufacture, and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the People's Republic of China. The company mainly manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The product line of the company includes cefaclor dispersible tablets, clarithromycin granules, roxithromycin dispersible tablets, andrographolide tablets, ozagrel sodium for injection, gastrodin injection, and others.